U.S. markets closed
  • S&P Futures

    4,359.25
    +15.75 (+0.36%)
     
  • Dow Futures

    34,297.00
    +122.00 (+0.36%)
     
  • Nasdaq Futures

    14,819.75
    +55.00 (+0.37%)
     
  • Russell 2000 Futures

    2,236.40
    +10.40 (+0.47%)
     
  • Crude Oil

    74.61
    -0.68 (-0.90%)
     
  • Gold

    1,734.60
    -2.90 (-0.17%)
     
  • Silver

    22.48
    +0.01 (+0.06%)
     
  • EUR/USD

    1.1688
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5340
    +0.0500 (+3.37%)
     
  • Vix

    23.25
    +4.49 (+23.93%)
     
  • GBP/USD

    1.3541
    +0.0001 (+0.01%)
     
  • USD/JPY

    111.5580
    +0.0780 (+0.07%)
     
  • BTC-USD

    41,012.05
    -1,373.34 (-3.24%)
     
  • CMC Crypto 200

    1,011.73
    -45.42 (-4.30%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    29,630.55
    -553.41 (-1.83%)
     

Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has approved Novartis AG’s (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or phototherapy.

  • The approved dosing is 75 mg or 150 mg depending on the child’s weight at the time of dosing and is administered by subcutaneous injection every four weeks after an initial loading regimen.

  • After initial counseling and proper training in injection technique, Cosentyx can be administered outside of a healthcare provider’s office via a single-dose prefilled syringe or Sensoready pen.

  • The approval is based on two Phase 3 studies. The data showed Cosentyx reduced psoriasis severity at Week 12 compared with placebo, as demonstrated by the following efficacy results by baseline.

  • Related content: Benzinga's Full FDA Calendar

  • Price Action: NVS shares are up 1.02% at $89.02 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.